Sweden · Delayed Price · Currency is SEK Isofol Medical AB Earnings Call Transcripts
Fiscal Year 2026
-
Arfolitixorin, a next-generation folate, is being developed to address the high unmet need in metastatic colorectal cancer, with promising early clinical results and a large commercial opportunity. Ongoing trials are expanding across multiple countries, and market research supports strong pricing potential if efficacy is demonstrated.
Fiscal Year 2025
-
Multiple clinical and financial milestones have been achieved, including a successful rights issue, FDA and Japanese regulatory progress, and a new patent extending exclusivity to 2043. The ongoing phase 1B/2 study is advancing with higher, well-tolerated doses and an improved design, supporting strong commercial and scientific potential.
-
Exited the quarter with a strengthened financial position after an oversubscribed rights issue and continued progress in clinical trials. R&D expenses increased, resulting in a higher net loss, but positive regulatory feedback and new partnerships support future growth.